AbbVie Inc. (ABBV)
3 More Cyclical Stocks to Buy for 2025
In last week's Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper miner Freeport–McMoRan Inc. ( FCX ) usually trade in a predetermined range (much like high and low tides at a beach), and so investors simply need to learn that range and the pattern the stock follows, and then buy low and sell high.
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline. Management expects a return to "robust" mid-single-digit revenue growth in 2025, which suggests full-year 2025 guidance will be largely in line with the analyst consensus. AbbVie is not giving up on emraclidine based on trial conduct and drug exposure observations in the failed phase trial in schizophrenia patients in late 2024.
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
Is AbbVie Stock a Buy?
Pharmaceutical powerhouse AbbVie (ABBV 0.87%) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising its dividend by an average of 14% annually.
What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
Many products sold by companies aren't must-have items. However, healthcare is a necessity.
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case?
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable environment, focusing on companies with resilient business models can provide stability. Coca-Cola, AbbVie, and TC Energy stand out in this regard. These stocks offer defensive growth, attractive dividends, and strong fundamentals. They're well-positioned to navigate inflation while providing consistent income and long-term returns.
